Sign in Subscribe
Nanotechnology

Breakthrough in Liver Cancer Treatment: Hypoxia-Responsive Nanoparticles Show Promising Results

Strategic Insights

— 1 min read

A team of researchers from China Agricultural University has made a significant discovery in the field of liver cancer treatment. By engineering nanoparticles that respond to hypoxia, the team was able to deliver chemotherapy drugs selectively to cancer cells, minimizing harm to healthy cells. The nanoparticles, called NI-HA-BMs-DOX, were tested in both cellular and in vivo studies, demonstrating improved efficacy in tumor cytotoxicity and apoptosis.

Key Takeaways:

  • The NI-HA-BMs-DOX nanoparticles were engineered with 2-nitroimidazole (NI), hyaluronic acid (HA), bacterial magnetosomes (BMs), and doxorubicin (DOX) for targeted drug delivery.
  • Under tumor hypoxia, the nanoparticles undergo a transition from a hydrophobic to a hydrophilic state, facilitating controlled DOX release.
  • In cellular assays, NI-HA-BMs-DOX demonstrated selective DOX delivery to HepG2 hepatocellular carcinoma cells, with minimal cytotoxicity toward normal hepatocytes.
  • In vivo studies showed that NI-HA-BMs-DOX (4 mg/kg DOX equivalent) achieved a tumor inhibition rate of 55.38%, exceeding that of HA-BMs-DOX (43.88%) and free DOX (34.90%).
  • The research highlights the potential of bacterial magnetosomes in improving drug delivery strategies for cancer treatment.
  • The findings validate NI-HA-BMs-DOX as a promising hypoxia-targeted therapeutic platform for HCC.

Statistics:

  • 55.38%: tumor inhibition rate achieved by NI-HA-BMs-DOX in in vivo studies
  • 43.88%: tumor inhibition rate achieved by HA-BMs-DOX in in vivo studies
  • 34.90%: tumor inhibition rate achieved by free DOX in in vivo studies
  • 4 mg/kg: DOX equivalent dosage of NI-HA-BMs-DOX in in vivo studies

Sources:

  • A promising platform of hypoxia sensitive magnetosomes in hepatocellular carcinoma therapy. Scientific Reports, 2025;15(1):25031. Scientific Reports can be contacted at: Nature Portfolio, Heidelberger Platz 3, Berlin, 14197, Germany. (Nature Publishing Group - www.nature.com/; Scientific Reports - www.nature.com/srep/)

Read more